icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Aug 27-29
Digital ILC 2020
Back grey_arrow_rt.gif
 
 
 
Direct-acting antiviral treatment in patients infected with a nonepidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study
 
 
  EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
 
Download the PDF here
 
Download the PDF here
 
C. Isfordink1,2, T. van de Laar3,4, S. Rebers1, E. Wessels5, R. Molenkamp6, M. Knoester7, B. Baak4, C. van Nieuwkoop8, B. van Hoek5, S. Brakenhoff6, H. Blokzijl7, J. Arends2, M. van der Valk1, J. Schinkel1, on behalf of the HepNed study group 1Amsterdam UMC, Amsterdam, the Netherlands (NL); 2UMC Utrecht, Utrecht, NL. 3Sanquin Research, Amsterdam, NL; 4OLVG, Amsterdam, NL; 5Leiden UMC, Leiden, NL; 6Erasmus MC, Rotterdam, NL; 7UMC Groningen, Groningen, NL; 8Haga Teaching Hospital, The Hague, NL
 
----------------------------------
 
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia
 
Research Needs Editorial - Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus
 
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. Childs et al. pdf attached
 
Treatment response
To date, 63 patients have completed DAA treatment and follow-up. Fifty-six of these patients have achieved an SVR, while 7 failed treatment, giving an overall SVR rate of 89%. As expected, response rates in genotypes 1a or 1b were uniformly high. Similarly, all patients infected with genotype 2, 3, 4 and 5 achieved an SVR. In those patients with unusual G1 and G4 African subtypes, treatment response according to genotype and choice of treatment regimen are shown in Table 2. An SVR was observed in only 21 of the 28 (75%) patients infected with unusual African genotype 1.
 
Five patients who failed initial treatment have thus far commenced retreatment: 3 of these patients have completed 16 weeks of glecaprevir and pibrentasvir, 2 of whom have achieved an SVR. One individual with cirrhosis and G1* HCV virus failed to achieve an SVR with 16 weeks of glecaprevir and pibrentasvir. Two other patients were retreated with sofosbuvir, velpatasvir and voxilaprevir and achieved an SVR.
 
Editorial - DAA failures in African patients with ''unusual'' HCV subtypes - Hey! Didn't you know there was another world? Jean-Michel Pawlotsky. Pdf attached

0921201

0921202

0921203

0921204

0921205

0921206